About us

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

In addition, the Company is developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA). There is a significant unmet clinical need in this patient population of elderly men. FT has completed a phase II trial in the United States in 147 men demonstrating important long-term (up to 5 year) clinical benefits in men receiving FT, including significant delay in disease progression compared to controls.

The Company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States and Switzerland. The Company is in the process of relocating its headquarters from the Bahamas to Switzerland.

The Company offers two diagnostic products that it has successfully developed: NicAlert® and TobacAlert® tests for measuring tobacco product exposure.

Nymox Pharmaceutical Corporation is a public company and its stock is traded on NASDAQ National Market under the symbol NYMX.


We are proud to play an active role in today’s medicine, collaboratively seeking to provide innovative and meaningful solutions for relevant medical problems.

Paul Averback, MD, DABP, President and CEO

Dr. Paul Averback is the founder, CEO and President of Nymox. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer’s disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. Dr. Averback holds a Diploma of the American Board of Pathology with special competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University, England, and was on the Faculty of Medicine at McGill University.

Suresh Kalbag, MD

Dr. Suresh Kalbag is Nymox’s Director of CMC Operations. Dr. Kalbag received his Ph.D. from Loyola University and did postdoctoral research at Indiana University School of Medicine. Dr. Kalbag has extensive first-hand and senior management experience in Research, Process Development, Manufacturing and QC at prestigious companies including Beckman, SmithKline, Genentech, and others, including experience at Ciba Research Center (Novartis) and the University of Basel.

James G. Robinson, Director

James G. Robinson, is the CEO of Morgan Creek Productions, which for over 25 years, has continued to be one of the leading and most successful independent production entities in the film business. Under Robinson’s leadership, Morgan Creek has produced an assortment of highly successful and critically acclaimed feature films.

Professor David Morse, Director

Professor David Morse, Ph.D. is a Professor at the University of Montreal and a world expert in the biochemistry, proteomics and genomics of cell function. Professor Morse has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Nature, Cell, Proceedings of the National Academy of Science, and the Journal of Biological Chemistry.